Gray JW - Search Results

1

Proteomic and transcriptomic profiling reveals a link between the PI3K pathway and lower estrogen-receptor (ER) levels and activity in ER+ breast cancer.

Creighton CJ, Fu X, Hennessy BT, Casa AJ, Zhang Y, Gonzalez-Angulo AM, Lluch A, Gray JW, Brown PH, Hilsenbeck SG, Osborne CK, Mills GB, Lee AV, Schiff R. Creighton CJ, et al. Among authors: gray jw. Breast Cancer Res. 2010;12(3):R40. doi: 10.1186/bcr2594. Epub 2010 Jun 22. Breast Cancer Res. 2010. PMID: 20569503 Free PMC article.

2

NOEY2 (ARHI), an imprinted putative tumor suppressor gene in ovarian and breast carcinomas.

Yu Y, Xu F, Peng H, Fang X, Zhao S, Li Y, Cuevas B, Kuo WL, Gray JW, Siciliano M, Mills GB, Bast RC Jr. Yu Y, et al. Among authors: gray jw. Proc Natl Acad Sci U S A. 1999 Jan 5;96(1):214-9. doi: 10.1073/pnas.96.1.214. Proc Natl Acad Sci U S A. 1999. PMID: 9874798 Free PMC article.

3

PIK3CA is implicated as an oncogene in ovarian cancer.

Shayesteh L, Lu Y, Kuo WL, Baldocchi R, Godfrey T, Collins C, Pinkel D, Powell B, Mills GB, Gray JW. Shayesteh L, et al. Among authors: gray jw. Nat Genet. 1999 Jan;21(1):99-102. doi: 10.1038/5042. Nat Genet. 1999. PMID: 9916799

4

In vivo and in vitro ovarian carcinoma growth inhibition by a phosphatidylinositol 3-kinase inhibitor (LY294002).

Hu L, Zaloudek C, Mills GB, Gray J, Jaffe RB. Hu L, et al. Clin Cancer Res. 2000 Mar;6(3):880-6. Clin Cancer Res. 2000. PMID: 10741711

5

An approach to analysis of large-scale correlations between genome changes and clinical endpoints in ovarian cancer.

Suzuki S, Moore DH 2nd, Ginzinger DG, Godfrey TE, Barclay J, Powell B, Pinkel D, Zaloudek C, Lu K, Mills G, Berchuck A, Gray JW. Suzuki S, et al. Among authors: gray jw. Cancer Res. 2000 Oct 1;60(19):5382-5. Cancer Res. 2000. PMID: 11034075

6

The role of genetic abnormalities of PTEN and the phosphatidylinositol 3-kinase pathway in breast and ovarian tumorigenesis, prognosis, and therapy.

Mills GB, Lu Y, Fang X, Wang H, Eder A, Mao M, Swaby R, Cheng KW, Stokoe D, Siminovitch K, Jaffe R, Gray J. Mills GB, et al. Semin Oncol. 2001 Oct;28(5 Suppl 16):125-41. doi: 10.1016/s0093-7754(01)90290-8. Semin Oncol. 2001. PMID: 11706404 Review.

7

Biallelic inactivation of the thyroid hormone receptor beta1 gene in early stage breast cancer.

Li Z, Meng ZH, Chandrasekaran R, Kuo WL, Collins CC, Gray JW, Dairkee SH. Li Z, et al. Among authors: gray jw. Cancer Res. 2002 Apr 1;62(7):1939-43. Cancer Res. 2002. PMID: 11929806

8

Genomic copy number analysis of non-small cell lung cancer using array comparative genomic hybridization: implications of the phosphatidylinositol 3-kinase pathway.

Massion PP, Kuo WL, Stokoe D, Olshen AB, Treseler PA, Chin K, Chen C, Polikoff D, Jain AN, Pinkel D, Albertson DG, Jablons DM, Gray JW. Massion PP, et al. Among authors: gray jw. Cancer Res. 2002 Jul 1;62(13):3636-40. Cancer Res. 2002. PMID: 12097266

9

Specific keynote: molecular therapeutics in ovarian cancer.

Mills GB, Fang X, Lu Y, Hasegawa Y, Eder A, Tanyi J, Tabassam FH, Mao M, Wang H, Cheng KW, Nakayama Y, Kuo W, Erickson J, Gershenson D, Kohn EC, Jaffe R, Bast RC Jr, Gray J. Mills GB, et al. Gynecol Oncol. 2003 Jan;88(1 Pt 2):S88-92; discussion S93-6. doi: 10.1006/gyno.2002.6692. Gynecol Oncol. 2003. PMID: 12586094 Review. No abstract available.

10

Linking molecular diagnostics to molecular therapeutics: targeting the PI3K pathway in breast cancer.

Mills GB, Kohn E, Lu Y, Eder A, Fang X, Wang H, Bast RC, Gray J, Jaffe R, Hortobagyi G. Mills GB, et al. Semin Oncol. 2003 Oct;30(5 Suppl 16):93-104. doi: 10.1053/j.seminoncol.2003.08.011. Semin Oncol. 2003. PMID: 14613030 Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

515 results

Search Page